Clinical Report: Lilly’s $7B In Vivo CAR-T Bet
Overview
Eli Lilly's acquisition of Kelonia Therapeutics for $7 billion aims to enhance its in vivo CAR-T cell therapy capabilities. The lead candidate, KLN-1010, is currently in Phase 1 trials and shows promising early efficacy and tolerability in treating multiple myeloma.
Background
The development of in vivo CAR-T therapies represents a significant advancement in cancer treatment, potentially simplifying the manufacturing process and improving patient access. Traditional ex vivo CAR-T therapies involve complex procedures that can delay treatment. The growing interest in in vivo strategies reflects a need for more efficient and accessible cancer therapies.
Data Highlights
No numerical data available in the provided material.
Key Findings
Focus solely on findings related to Lilly and Kelonia, removing unrelated information.Clinical Implications
Detail how in vivo CAR-T therapies could specifically change treatment protocols.
Conclusion
The move towards in vivo CAR-T therapies signifies a pivotal shift in cancer treatment, with potential benefits in accessibility and efficiency. Continued monitoring of clinical outcomes will be essential as these therapies develop.
Related Resources & Content
- Franklin / MDSpire, Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
- The ASCO Post, Early Findings From First Human Study of In Vivo CAR T in Myeloma
- The ASCO Post, CAR T-Cell Therapy for DLBCL: At the Crossroads of Hype and Reality
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PubMed
- In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery
- Franklin / MDSpire — Current Ex Vivo CAR-T Benchmarks Define the Bar for Emerging In Vivo CRISPR-Based T Cell Engineering
- the medicine maker — Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
- Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?
- NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
- Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study - PubMed
- In vivo chimeric antigen receptor (CAR)-T cell therapy | Nature Reviews Drug Discovery
Based on findings from:
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet
The Medicine Maker, 2026.
https://www.themedicinemaker.com/issues/2026/articles/april/this-weeks-cgt-news-lillys-7b-in-vivo-cart-bet/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
